

SARS-CoV-2 vaccination induces immunological T cell responses to multiple variants from Alpha to Omicron

Cell

185, 847-859.e11

DOI: [10.1016/j.cell.2022.01.015](https://doi.org/10.1016/j.cell.2022.01.015)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. <i>Cell Reports Medicine</i> , 2022, 3, 100527.	3.3	47
4	T cell responses to SARS-CoV-2 spike cross-recognize Omicron. <i>Nature</i> , 2022, 603, 488-492.	13.7	430
5	SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron. <i>Frontiers in Immunology</i> , 2022, 13, 801431.	2.2	31
6	What the Omicron wave is revealing about human immunity. <i>Nature</i> , 2022, 602, 22-25.	13.7	35
8	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
9	A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.. <i>Immunology Letters</i> , 2022, 243, 38-43.	1.1	18
12	Cross reactive T cells hold up against Omicron. <i>Nature Reviews Immunology</i> , 2022, 22, 146-146.	10.6	8
15	Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>JAMA Neurology</i> , 2022, 79, 399.	4.5	67
17	Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. <i>Npj Vaccines</i> , 2022, 7, 35.	2.9	34
18	Count on us: T cells in SARS-CoV-2 infection and vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100562.	3.3	86
19	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
21	The (apparent) antibody paradox in COVID-19. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 335-345.	1.3	9
22	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
24	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
25	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
27	Antibodies: A Double Leg Takedown Against COVID-19. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	0
32	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <i>Cell Host and Microbe</i> , 2022, 30, 880-886.e4.	5.1	80
33	Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab. <i>Annals of Neurology</i> , 2022, 91, 796-800.	2.8	26

#	ARTICLE	IF	CITATIONS
34	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. <i>Science Immunology</i> , 2022, 7, eabo0535.	5.6	17
35	Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1873-1883.	2.6	37
36	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
37	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. <i>Cell</i> , 2022, 185, 1875-1887.e8.	13.5	148
38	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	6.6	42
39	The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine. <i>Journal of Virology</i> , 2022, 96, e0017722.	1.5	10
40	Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 1314-1326.	13.9	303
41	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
42	SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. <i>JCI Insight</i> , 2022, 7, .	2.3	15
44	Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection?. <i>Frontiers in Medicine</i> , 2022, 9, 852998.	1.2	25
45	Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein. <i>Frontiers in Immunology</i> , 2022, 13, 875236.	2.2	2
46	Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients. <i>Clinical Infectious Diseases</i> , 2022, 75, 1652-1654.	2.9	4
47	Visualizing omicron: COVID-19 deaths vs. cases over time. <i>PLoS ONE</i> , 2022, 17, e0265233.	1.1	12
48	Can B cell-deficient patients rely on COVID-19 vaccine-induced T cell immunity?. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
49	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. <i>Journal of Infectious Diseases</i> , 2022, 226, 1551-1555.	1.9	4
50	Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals. <i>JAMA Network Open</i> , 2022, 5, e2210871.	2.8	42
51	Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 689-699.	5.2	108
52	The Evolution and Biology of SARS-CoV-2 Variants. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a041390.	2.9	110

#	ARTICLE	IF	CITATIONS
53	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. <i>Viruses</i> , 2022, 14, 882.	1.5	3
54	Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. <i>Blood</i> , 2022, 140, 156-160.	0.6	10
55	SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls. <i>Vaccines</i> , 2022, 10, 694.	2.1	6
56	Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 933.	1.5	13
57	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	7.1	315
58	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996.	1.4	3
59	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. <i>Nature Reviews Immunology</i> , 2022, 22, 387-397.	10.6	93
60	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
61	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	24
62	TNF-Î±+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100640.	3.3	15
63	Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	20
64	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. <i>Clinical and Experimental Immunology</i> , 2022, 209, 90-98.	1.1	5
65	Inducing broad-based immunity against viruses with pandemic potential. <i>Immunity</i> , 2022, 55, 738-748.	6.6	16
66	Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-19.	1.4	20
67	Mucosal immune responses to infection and vaccination in the respiratory tract. <i>Immunity</i> , 2022, 55, 749-780.	6.6	66
68	Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years. <i>Journal of Clinical Medicine</i> , 2022, 11, 2649.	1.0	8
69	T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3998-4004.	2.5	20
70	Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103863.	0.9	6

#	ARTICLE	IF	CITATIONS
71	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. <i>Immunity</i> , 2022, 55, 945-964.	6.6	32
72	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
73	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. <i>Nature Microbiology</i> , 2022, 7, 909-917.	5.9	41
74	Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	15
75	Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved. <i>Journal of Immunology</i> , 2022, 208, 2461-2465.	0.4	10
78	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	4.3	54
79	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. <i>EBioMedicine</i> , 2022, 80, 104073.	2.7	28
80	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	1.8	7
81	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	18
82	Bioinformatic and Experimental Analysis of T Cell Immune Reactivity to SARS-CoV-2 and its Variants. <i>Frontiers in Bioinformatics</i> , 2022, 2, .	1.0	6
83	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	13.5	289
86	Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6083.	1.8	10
87	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. <i>Vaccines</i> , 2022, 10, 794.	2.1	5
88	High Level of SARS-CoV-2 Infection in Young Population Is a Predictor for Peak Incidence. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	1
89	The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1524-1536.	3.0	39
90	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
91	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. <i>Immunological Reviews</i> , 2022, 310, 6-26.	2.8	138
92	Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2% years after allogeneic bone marrow transplant. <i>British Journal of Haematology</i> , 2022, 198, 668-679.	1.2	13

#	ARTICLE	IF	CITATIONS
94	Omicron Reactive Multi Protein Specific CD4 T Cells Defines Cellular Immune Response Induced by Inactivated Virus Vaccines. SSRN Electronic Journal, 0, , .	0.4	2
95	Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boule-SEI awards: A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boule Group to honor the Balmis Expedition. Current Research in Immunology, 2022, 3, 136-145.	1.2	0
96	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	2.2	4
97	Antibody- and T Cell-Dependent Responses Elicited by a SARS-CoV-2 Adenoviral-Based Vaccine in a Socially Vulnerable Cohort of Elderly Individuals. Vaccines, 2022, 10, 937.	2.1	1
99	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. Vaccines, 2022, 10, 904.	2.1	7
100	Considerations of CD8+ T Cells for Optimized Vaccine Strategies Against Respiratory Viruses. Frontiers in Immunology, 0, 13, .	2.2	8
101	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	9.4	29
102	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	1.2	24
103	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6â€“17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet, The, 2022, 399, 2212-2225.	6.3	23
104	Durability of Immune Responses After Boosting in Ad26.COVID.S-Primed Healthcare Workers. Clinical Infectious Diseases, 2023, 76, e533-e536.	2.9	7
105	Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group. Nephrology Dialysis Transplantation, 2022, 37, 1824-1829.	0.4	6
106	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. Frontiers in Immunology, 0, 13, .	2.2	0
107	Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood. ImmunoHorizons, 2022, 6, 398-407.	0.8	0
108	Immunological memory to <sc>SARSâ€CoV</sc>â€2 infection and <sc>COVID</sc>â€19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
109	Clinical and Genetic Characteristics of Coronaviruses with Particular Emphasis on SARS-CoV-2 Virus. Polish Journal of Microbiology, 2022, 71, 141-159.	0.6	0
110	Immune boosting by B.1.1.529 Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	6.0	241
111	Cellular immunity in patients with COVID-19: molecular biology, pathophysiology, and clinical implications. Journal of Clinical Practice, 2022, 13, 66-87.	0.2	1
114	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	2.1	3

#	ARTICLE	IF	CITATIONS
115	Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	6
116	Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis. <i>EBioMedicine</i> , 2022, 81, 104102.	2.7	30
117	Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
118	Asymptomatic or Symptomatic SARS-CoV-2 Infection Plus Vaccination Confers Increased Adaptive Immunity to Variants of Concern of SARS-CoV-2 Including Omicron. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
119	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1050.	2.1	3
120	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. <i>Nature Communications</i> , 2022, 13, .	5.8	42
121	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. <i>Vaccines</i> , 2022, 10, 1031.	2.1	6
122	A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge. <i>Virology Journal</i> , 2022, 19, .	1.4	1
123	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
124	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7155.	1.8	31
125	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11
126	Immunogenicity and efficacy of Ad26.<sc>COV2</sc>.<sc>S</sc>.S: An adenoviral vector-based <sc>COVID</sc>-19 vaccine. <i>Immunological Reviews</i> , 2022, 310, 47-60.	2.8	10
127	mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. <i>Vaccines</i> , 2022, 10, 1057.	2.1	11
128	T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine. , 2022, 10, e004953.		7
129	Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. <i>Immunity</i> , 2022, 55, 1732-1746.e5.	6.6	40
130	Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization. <i>Journal of Clinical Immunology</i> , 2022, 42, 1379-1391.	2.0	18
131	The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1123.	2.1	4
132	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. <i>Lancet Rheumatology</i> , The, 2022, 4, e582-e585.	2.2	9

#	ARTICLE	IF	CITATIONS
133	Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. <i>ELife</i> , 0, 11, .	2.8	11
134	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
135	A booster dose of Delta-Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
136	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
137	Guardians of the oral and nasopharyngeal galaxy: <sc>IgA</sc> and protection against <sc>SARS-CoV-2</sc> infection*. <i>Immunological Reviews</i> , 2022, 309, 75-85.	2.8	32
138	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. <i>Nature Communications</i> , 2022, 13, .	5.8	43
139	SARS-CoV-2 infection in a stem cell transplant recipient grafted from a SARS-CoV-2-positive donor. <i>Bone Marrow Transplantation</i> , 2022, 57, 1604-1606.	1.3	3
140	A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. <i>Journal of Clinical Medicine</i> , 2022, 11, 4164.	1.0	15
141	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
142	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 122, 793-801.	1.5	17
143	Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector. <i>Vaccines</i> , 2022, 10, 1142.	2.1	7
144	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
145	Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. <i>IScience</i> , 2022, 25, 104745.	1.9	11
146	Post-vaccination T cell immunity to omicron. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
147	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
148	Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. <i>Viruses</i> , 2022, 14, 1570.	1.5	10
149	“Don’t Look Up—Your Science—Herd Immunity or Herd Mentality?”. <i>Microorganisms</i> , 2022, 10, 1463.	1.6	2
150	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. <i>Science Immunology</i> , 2022, 7, .	5.6	170

#	ARTICLE	IF	CITATIONS
151	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. <i>Science</i> , 2022, 377, 890-894.	6.0	142
153	The Relative Positioning of B and T Cell Epitopes Drives Immunodominance. <i>Vaccines</i> , 2022, 10, 1227.	2.1	2
154	Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. <i>Viruses</i> , 2022, 14, 1642.	1.5	4
155	Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. <i>Cell Host and Microbe</i> , 2022, 30, 1269-1278.e4.	5.1	21
156	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
157	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
158	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1585-1593.	0.5	12
159	Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
160	SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. <i>Cell Reports</i> , 2022, 40, 111284.	2.9	4
163	A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. <i>MBio</i> , 2022, 13, .	1.8	28
165	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. <i>JAMA Network Open</i> , 2022, 5, e2226335.	2.8	42
166	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. <i>MSphere</i> , 2022, 7, .	1.3	8
167	BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	29
168	T cell immunity to COVID-19 vaccines. <i>Science</i> , 2022, 377, 821-822.	6.0	117
169	Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
172	Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	36
173	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
174	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27

#	ARTICLE	IF	CITATIONS
175	CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. <i>Science Immunology</i> , 2022, 7, .	5.6	74
176	NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	34
177	The New SARS-CoV-2 Variants and Their Epidemiological Impact in Mexico. <i>MBio</i> , 2022, 13, .	1.8	6
178	SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. <i>Immunity</i> , 2022, 55, 1764-1778.	6.6	63
179	Vaccination in patients with kidney failure: lessons from COVID-19. <i>Nature Reviews Nephrology</i> , 2022, 18, 708-723.	4.1	46
180	Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100716.	3.3	16
181	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
182	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
183	Decrease in CD8+CD45+CCR7+CD62L+ T cells in individuals vaccinated with Sinovac-CoronaVac following COVID-19 infection. <i>Clinical Immunology</i> , 2022, 242, 109092.	1.4	2
184	Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon- γ release assay. <i>International Journal of Infectious Diseases</i> , 2022, 122, 841-849.	1.5	24
187	Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. , 2022, 2, 196-206.		6
189	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10679.	1.8	5
190	Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. <i>Clinical Immunology</i> , 2022, 244, 109103.	1.4	3
191	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
192	SARS-CoV-2 Infection of Lung Organoids Reveals Conserved Use of Tetraspanin-8 by Ancestral-, Delta-, and Omicron- Variants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
193	Robust T Cell Responses to the Pfizer/Biontech Vaccine Compared to Infection and Evidence of Attenuated Cd8+ T Cell Responses Due to Covid-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
194	High-resolution analysis of individual spike peptide-specific CD4+ T cell responses in vaccine recipients and COVID-19 patients. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
195	T cells in SARS-CoV-2 infection and vaccination. , 2022, 10, 251513552211150.	1.4	4

#	ARTICLE	IF	CITATIONS
196	From Alpha to omicron: The response of T cells. <i>Current Research in Immunology</i> , 2022, 3, 146-150.	1.2	19
197	Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. <i>Viruses</i> , 2022, 14, 1916.	1.5	7
198	Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era. <i>Cancers</i> , 2022, 14, 4252.	1.7	3
199	Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors. <i>Vaccines</i> , 2022, 10, 1617.	2.1	0
200	Covid-19 Vaccines – Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
201	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. <i>IScience</i> , 2022, 25, 105209.	1.9	2
202	The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition. <i>Nature Communications</i> , 2022, 13, .	5.8	15
203	Immunogenicity and safety of two-dose SARS-CoV-2 vaccination via different platforms in kidney transplantation recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
205	Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. <i>Nature Immunology</i> , 2022, 23, 1445-1456.	7.0	27
206	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. <i>Emerging Microbes and Infections</i> , 2022, 11, 2412-2422.	3.0	10
207	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
209	The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	71
210	Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern. <i>IScience</i> , 2022, 25, 105202.	1.9	3
211	Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
212	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
213	Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
214	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
216	Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases. <i>RMD Open</i> , 2022, 8, e002622.	1.8	3

#	ARTICLE	IF	CITATIONS
217	Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
218	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11325.	1.8	6
219	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. <i>Npj Vaccines</i> , 2022, 7, .	2.9	3
221	Learning from our differences. <i>Nature Immunology</i> , 0, , .	7.0	0
222	Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
224	Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition. <i>Vaccines</i> , 2022, 10, 1563.	2.1	4
225	Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. <i>OncImmunology</i> , 2022, 11, .	2.1	10
226	Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients. <i>Cells</i> , 2022, 11, 3010.	1.8	3
227	Increased <sc>CD8</sc> Tâ€cell immunity after <sc>COVID</sc>â€19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3
228	Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
229	Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
230	A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
231	Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. <i>PLoS Pathogens</i> , 2022, 18, e1010885.	2.1	10
232	Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines. <i>Journal of Rheumatology</i> , 2022, 49, 1385-1389.	1.0	9
233	Protein vaccine NVX-CoV2373 elicits functional T cell immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
234	Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
235	A comparative characterization of SARS-CoV-2-specific Tâ€cells induced by mRNA or inactive virus COVID-19 vaccines. <i>Cell Reports Medicine</i> , 2022, 3, 100793.	3.3	26
236	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. <i>EBioMedicine</i> , 2022, 85, 104294.	2.7	11

#	ARTICLE	IF	CITATIONS
237	Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19?. <i>Neurological Sciences</i> , 2023, 44, 659-665.	0.9	5
238	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2022, 10, 1784.	2.1	1
240	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
241	Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
242	Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1677.	2.1	0
246	Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection. <i>Npj Vaccines</i> , 2022, 7, .	2.9	12
247	Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. <i>PLoS ONE</i> , 2022, 17, e0276241.	1.1	5
248	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
249	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. <i>Nature Medicine</i> , 2023, 29, 247-257.	15.2	98
250	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.	2.1	7
252	SARS-CoV-2 infected children form early immune memory responses dominated by nucleocapsid-specific CD8+ T cells and antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
253	Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. <i>Science Immunology</i> , 2022, 7, .	5.6	39
254	Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. <i>International Journal of Infectious Diseases</i> , 2022, 125, 195-208.	1.5	21
255	Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. <i>IScience</i> , 2022, 25, 105479.	1.9	24
256	NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. <i>Journal of Clinical Virology</i> , 2022, 157, 105321.	1.6	17
258	Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines. <i>Virologica Sinica</i> , 2022, 37, 783-785.	1.2	2
259	Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
260	Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4

#	ARTICLE	IF	CITATIONS
261	Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the QuantiFERON SARS-CoV-2 assay. <i>Pulmonology</i> , 2022, , .	1.0	4
262	The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
263	Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 635-646.	3.2	8
264	Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
265	Antigen specific T cells in people with obesity at five months following ChAdOx1 COVID-19 vaccination. <i>International Journal of Obesity</i> , 2023, 47, 83-86.	1.6	4
266	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	1.6	10
267	SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. <i>Seminars in Hematology</i> , 2022, 59, 192-197.	1.8	5
268	Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	12
269	Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14.	1.9	105
270	Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. <i>Journal of Infectious Diseases</i> , 2023, 227, 651-662.	1.9	7
271	A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. <i>Virus Research</i> , 2023, 324, 199024.	1.1	5
272	Ad26.COVS priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. <i>IScience</i> , 2023, 26, 105753.	1.9	4
273	SARS-CoV-2 epitopes inform future vaccination strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
274	SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. <i>ELife</i> , 0, 11, .	2.8	15
275	Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	1
276	Current understanding of T cell immunity against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	11
278	<i>Clinical Chemistry and Laboratory Medicine</i> celebrates 60 years“ narrative review devoted to the contribution of the journal to the diagnosis of SARS-CoV-2. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 811-821.	1.4	7
279	Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14367.	1.8	4

#	ARTICLE	IF	CITATIONS
280	Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
281	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. <i>Nature Communications</i> , 2022, 13, .	5.8	5
283	The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
284	Unique properties of tissue-resident memory T cells in the lungs: implications for COVID-19 and other respiratory diseases. <i>Nature Reviews Immunology</i> , 2023, 23, 329-335.	10.6	11
286	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	10
288	In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
289	Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations. <i>Annals of Laboratory Medicine</i> , 2023, 43, 290-294.	1.2	1
291	COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. <i>Cell Discovery</i> , 2022, 8, .	3.1	3
292	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
293	Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. <i>Cell Host and Microbe</i> , 2022, 30, 1662-1670.e4.	5.1	29
294	Omicron infection increases IgG binding to spike protein of predecessor variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
295	Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. <i>Blood Cancer Discovery</i> , 2023, 4, 106-117.	2.6	14
296	BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	42
297	Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition. <i>Nature Immunology</i> , 2022, 23, 1726-1734.	7.0	11
298	Utilization of SARS-CoV-2 RNA-Positive donors in pediatric renal transplantation. <i>Pediatric Transplantation</i> , 2023, 27, .	0.5	2
299	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
300	Impact of SARS-CoV-2 exposure history on the T cell and IgG response. <i>Cell Reports Medicine</i> , 2023, 4, 100898.	3.3	13
301	A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. <i>Npj Vaccines</i> , 2022, 7, .	2.9	20

#	ARTICLE	IF	CITATIONS
302	Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. <i>Vaccines</i> , 2022, 10, 2132.	2.1	6
305	Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	2
306	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
307	A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. <i>Cell Reports Methods</i> , 2023, 3, 100388.	1.4	1
308	Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza. <i>Journal of Immunology</i> , 2023, 210, 628-639.	0.4	1
309	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
310	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
312	A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4291-4304.	5.7	2
313	A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
315	Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine. <i>EBioMedicine</i> , 2023, 88, 104435.	2.7	20
316	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. <i>International Journal of Infectious Diseases</i> , 2023, 128, 112-120.	1.5	6
317	SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals. <i>Viruses</i> , 2023, 15, 101.	1.5	5
318	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222.	0.0	0
319	Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. <i>Journal of Immunology</i> , 2022, 209, 2104-2113.	0.4	8
320	Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients. <i>Chinese Medical Journal</i> , 2022, 135, 2656-2666.	0.9	1
322	Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
324	Evolution of SARS-CoV-2-specific CD4+ T cell epitopes. <i>Immunogenetics</i> , 2023, 75, 283-293.	1.2	2
325	Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
326	Positive-strand RNA viruses—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1521, 46-66.	1.8	0
327	Immunological and metabolic characteristics of the Omicron variants infection. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	2
329	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
330	Viral immunity: Basic mechanisms and therapeutic applications—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1521, 32-45.	1.8	0
332	Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
333	Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
334	Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
335	Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. <i>Nature Communications</i> , 2023, 14, .	5.8	10
336	Ad26.COVS.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. <i>Cell Reports Medicine</i> , 2023, 4, 101018.	3.3	3
338	T-cell activation-induced marker assays in health and disease. <i>Immunology and Cell Biology</i> , 2023, 101, 491-503.	1.0	12
339	A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. <i>Vaccine</i> , 2023, 41, 2101-2112.	1.7	6
340	Spheromers reveal robust T-cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T-cell responses post SARS-CoV-2 infection. <i>Immunity</i> , 2023, 56, 864-878.e4.	6.6	28
341	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. <i>Vaccines</i> , 2023, 11, 806.	2.1	1
342	A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	0
343	Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients. <i>Journal of Clinical Virology</i> , 2023, 162, 105428.	1.6	9
344	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
345	Understanding the mechanisms for COVID-19 vaccine™s protection against infection and severe disease. <i>Expert Review of Vaccines</i> , 2023, 22, 186-192.	2.0	6
346	Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. <i>Clinical and Experimental Immunology</i> , 2023, 211, 280-287.	1.1	2

#	ARTICLE	IF	CITATIONS
347	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. <i>Pathogens</i> , 2023, 12, 244.	1.2	8
348	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. <i>European Journal of Epidemiology</i> , 2023, 38, 237-242.	2.5	7
350	T Cell Responses to SARS-CoV-2. <i>Annual Review of Immunology</i> , 2023, 41, 343-373.	9.5	48
351	Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection. <i>Cellular Immunology</i> , 2023, 385, 104689.	1.4	1
352	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
353	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. <i>Med</i> , 2023, 4, 191-215.e9.	2.2	16
354	Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
355	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
357	Evaluation of QuantiFERON SARS-CoV-2 interferon- γ release assay following SARS-CoV-2 infection and vaccination. <i>Clinical and Experimental Immunology</i> , 2023, 212, 249-261.	1.1	8
358	Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2023, 71, .	1.0	4
361	A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	1
362	Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
363	Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
364	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
366	Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
367	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
368	Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine. <i>MedComm</i> , 2023, 4, .	3.1	2
369	Disease Course, Management and Outcomes in Kidney Transplant Recipients with SARS-CoV-2 Infection during the Omicron-Variant Wave: A Single-Center Experience. <i>Vaccines</i> , 2023, 11, 632.	2.1	2

#	ARTICLE	IF	CITATIONS
370	Bidirectional Relationship between Glycemic Control and COVID-19 and Perspectives of Islet Organoid Models of SARS-CoV-2 Infection. <i>Biomedicines</i> , 2023, 11, 856.	1.4	0
371	Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
372	A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. <i>Immunotherapy Advances</i> , 2023, 3, .	1.2	2
373	Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
374	Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice. <i>Viruses</i> , 2023, 15, 763.	1.5	4
376	Architecture of the SARS-CoV-2-specific T cell repertoire. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
377	Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
378	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. <i>Blood Advances</i> , 0, , .	2.5	1
379	Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
380	Durability of immune responses to mRNA booster vaccination against COVID-19. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	18
381	SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1652-1660.	1.4	3
382	Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage. <i>Lancet Microbe</i> , The, 2023, 4, e388.	3.4	5
383	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2
385	Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	1
386	<sc>ChAdOx1 nCoV</sc> â€19 vaccination generates spikeâ€specific <sc>CD8</sc> ⁺ T cells in aged mice. <i>Immunology and Cell Biology</i> , 0, , .	1.0	0
387	Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
388	FcÎ³R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 569-580.	5.9	33
389	Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination. <i>Microorganisms</i> , 2023, 11, 940.	1.6	1

#	ARTICLE	IF	CITATIONS
390	An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. <i>Nature Communications</i> , 2023, 14, .	5.8	11
391	Immune interference in effectiveness of influenza and COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
392	Evaluation of T _H 1 cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination. <i>Cell Reports</i> , 2023, 42, 112470.	2.9	0
393	Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 901-913.	4.6	11
399	Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	15
405	Retroviral, lentiviral pathogens impacting human health. , 2023, , 65-79.		0
407	Zoonoses and anthroponoses: Reverse transmission of pathogens. , 2023, , 1-49.		0
456	Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1305-1313.	3.2	11
460	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
553	In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. , 2024, 21, 103-118.		4
556	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3
583	Detection of SARS-CoV-2-Specific Cells Utilizing Whole Proteins and/or Peptides in Human PBMCs Using IFN- γ ELISPOT Assay. <i>Methods in Molecular Biology</i> , 2024, , 117-133.	0.4	0